OBJECTIVES: Deficit in visuospatial functions can influence both simple and complex daily life activities. Despite the fact that visuospatial deficit was reported in schizophrenia, research on visuospatial functions as an independent entity is limited. Our study aims to elucidate the impact of visuospatial deficit in comparison with verbal deficit on global functioning and quality of life in the first psychotic episode of schizophrenia spectrum disorder (FES). The significance of clinical symptoms and antipsychotic medication was also studied. METHODS: Thirty-six FES patients and a matched group of healthy controls (HC group) were assessed with a neuropsychological battery focused on visuospatial (VIS) and verbal (VERB) functions. Using multiple regression analysis, we evaluated the cumulative effect of VERB and VIS functions, psychiatric symptoms (PANSS) and antipsychotic medication on global functioning (GAF) and quality of life (WHOQOL-BREF) in the FES group. RESULTS: The FES group demonstrated significant impairment both in VIS and VERB cognitive abilities compared to the HC group. Antipsychotic medication did not significantly affect either VIS or VERB functioning. PANSS was not related to cognitive functioning, apart from the Trail Making Test B. In the FES group, the GAF score was significantly affected by the severity of positive symptoms and VERB functioning, explaining together 60% of GAF variability. The severity of negative and positive symptoms affected only the Physical health domain of WHOQOL-BREF. The degree of VERB deficit was associated with both Physical and Psychological health. Although we did not find any relation between VIS functioning, GAF, and WHOQOL-BREF, a paradoxical finding emerged in the Environment quality domain, where a worse quality of the environment was associated with better VIS functioning. CONCLUSIONS: Our results suggest that the deficit in VIS functions is an integral part of cognitive deficit in schizophrenia spectrum disorders, rather than a side effect of symptomatology or antipsychotic medication. Moreover, VERB functioning was a better predictor of GAF and WHOQOL-BREF than VIS functioning. Given the findings of negative or missing effect of VIS deficit on WHOQOL-BREF and GAF, the accuracy of these measures in evaluating the impact of global cognitive deficit on everyday life in schizophrenia could be questioned.

Department of Neurophysiology of Memory Institute of Physiology of the Czech Academy of Sciences Prague Czech Republic

Department of Psychiatry and Medical Psychology 3rd Faculty of Medicine Charles University Prague Czech Republic

National IT System of Mental Health and Brain Monitoring National Institute of Mental Health Klecany Czech Republic

National IT System of Mental Health and Brain Monitoring National Institute of Mental HealthKlecany Czech Republic; Department of Neurophysiology of Memory Institute of Physiology of the Czech Academy of SciencesPrague Czech Republic

National IT System of Mental Health and Brain Monitoring National Institute of Mental HealthKlecany Czech Republic; Department of Psychiatry and Medical Psychology 3rd Faculty of Medicine Charles University PraguePrague Czech Republic

National IT System of Mental Health and Brain Monitoring National Institute of Mental HealthKlecany Czech Republic; Department of Psychiatry and Medical Psychology 3rd Faculty of Medicine Charles University PraguePrague Czech Republic; Department of Neurophysiology of Memory Institute of Physiology of the Czech Academy of SciencesPrague Czech Republic

Zobrazit více v PubMed

Addington J., Addington D., Maticka-Tyndale E. (1991). Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophr. Res. 5, 123–134. 10.1016/0920-9964(91)90039-T PubMed DOI

Aksaray G., Oflu S., Kaptanoglu C., Bal C. (2002). Neurocognitive deficits and quality of life in outpatients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 26, 1217–1219. 10.1016/S0278-5846(02)00217-8 PubMed DOI

Andreasen N. C., Carpenter W. T., Jr., Kane J. M., Lasser R. A., Marder S. R., Weinberger D. R. (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiatry 162, 441–449. 10.1176/appi.ajp.162.3.441 PubMed DOI

Andreasen N. C., Pressler M., Nopoulos P., Miller D., Ho B. C. (2010). Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 67, 255–262. 10.1016/j.biopsych.2009.08.040 PubMed DOI PMC

Arana G. W. (2000). An overview of side effects caused by typical antipsychotics. J. Clin. Psychiatry 61(Suppl. 8), 5–11. Available online at: http://www.psychiatrist.com/JCP/article/Pages/2000/v61s08/v61s08002a.aspx PubMed

Bilder R. M., Goldman R. S., Robinson D., Reiter G., Bell L., Bates J. A., et al. . (2000). Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry 157, 549–559. 10.1176/appi.ajp.157.4.549 PubMed DOI

Bilder R. M., Turkel E., Lipschutz-Broch L., Lieberman J. A. (1992). Antipsychotic medication effects on neuropsychological functions. Psychopharmacol. Bull. 28, 353–366. PubMed

Bowie C. R., Twamley E. W., Anderson H., Halpern B., Patterson T. L., Harvey P. D. (2007). Self-assessment of functional status in schizophrenia. J. Psychiatr. Res. 41, 1012–1018. 10.1016/j.jpsychires.2006.08.003 PubMed DOI PMC

Bubeníková V., Votava M., Horáček J., Páleníček T., Dockery C. (2005). The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. Pharmacol. Biochem. Behav. 80, 591–596. 10.1016/j.pbb.2005.01.012 PubMed DOI

Butler P. D., Zemon V., Schechter I., Saperstein A. M., Hoptman M. J., Lim K. O., et al. . (2005). Early-stage visual processing and cortical amplification deficits in schizophrenia. Arch. Gen. Psychiatry 62, 495–504. 10.1001/archpsyc.62.5.495 PubMed DOI PMC

Černochová D., Goldmann P., Král P., Soukupová T., Šnorek P., Havlůj V. (2010). Wechslerova Inteligenční škála Pro Dospělé WAIS-III. Praha: Hogrefe-Test Centrum.

Chaplin R., Barley M., Cooper S. J., Kusel Y., McKendrick J., Stephenson D., et al. . (2006). The impact of intellectual functioning on symptoms and service use in schizophrenia. J. Intellect. Disabil. Res. 50, 288–294. 10.1111/j.1365-2788.2006.00837.x PubMed DOI

Cocchi L., Bosisio F., Berchtold A., Orita A., Debbané M., Wood S. J., et al. . (2009). Visuospatial encoding deficits and compensatory strategies in schizophrenia revealed by eye movement analysis during a working memory task. Acta Neuropsychiatr. 21, 75–83. 10.1111/j.1601-5215.2009.00369.x PubMed DOI

Cummings J. L., Mega M. S. (2003). Visuospatial, visuoperceptual, and right hemisphere disturbances, in Neuropsychiatry and Behavioral Neuroscience, eds Cummings J. L., Mega M. S. (NewYork, NY: Oxford University Press; ), 114–127.

de Vignemont F., Zalla T., Posada A., Louvegnez A., Koenig O., Georgieff N., et al. . (2006). Mental rotation in schizophrenia. Conscious. Cogn. 15, 295–309. 10.1016/j.concog.2005.08.001 PubMed DOI

Dinges D. F., Orne M. T., Orne E. C. (1985). Assessing performance upon abrupt awakening from naps during quasi-continuous operations. Behav. Res. Methods Instrum. Comput. 17, 37–45. 10.3758/BF03200895 DOI

Doniger G. M., Silipo G., Rabinowicz E. F., Snodgrass J. G., Javitt D. C. (2001). Impaired sensory processing as a basis for object-recognition deficits in schizophrenia. Am. J. Psychiatry 158, 1818–1826. 10.1176/appi.ajp.158.11.1818 PubMed DOI

Dragomirecká E., Bartoňová J. (2006a). Dotazník kvality života Světové zdravotnické organizace WHOQOL-BREF: Psychometrické vlastnosti a první zkušenosti s českou verzí (The World Health Organization quality of life assessment WHOQOL_BREF. Psychometric properties and first experience with czech version). Psychiatrie 10, 144–149. Available online at: http://www.tigis.cz/images/stories/psychiatrie/2006/03/02_dragomirec_psych_3-06.pdf

Dragomirecká E., Bartoňová J. (2006b). WHOQOL-BREF, WHOQOL-100: World Health Organization Quality of Life Assessment: příručka pro uživatele české verze dotazníků kvality života Světové zdravotnické organizace. Praha: Psychiatrické centrum Praha.

Eack S. M., Newhill C. E. (2007). Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr. Bull. 33, 1225–1237. 10.1093/schbul/sbl071 PubMed DOI PMC

Evans J. J., Chua S. E., McKenna P. J., Wilson B. A. (1997). Assessment of the dysexecutive syndrome in schizophrenia. Psychol. Med. 27, 635–646. 10.1017/S0033291797004790 PubMed DOI

Fajnerová I., Rodriguez M., Levčík D., Konrádová L., Mikoláš P., Brom C., et al. . (2014). A virtual reality task based on animal research - spatial learning and memory in patients after the first episode of schizophrenia. Front. Behav. Neurosci. 8:157. 10.3389/fnbeh.2014.00157 PubMed DOI PMC

Fiszdon J. M., Choi J., Goulet J., Bell M. D. (2008). Temporal relationship between change in cognition and change in functioning in schizophrenia. Schizophr. Res. 105, 105–113. 10.1016/j.schres.2008.06.010 PubMed DOI

Fioravanti M., Carlone O., Vitale B., Cinti M. E., Clare L. (2005). A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychol. Rev. 15, 73–95. 10.1007/s11065-005-6254-9 PubMed DOI

Folley B. S., Astur R., Jagannathan K., Calhoun V. D., Pearlson G. D. (2010). Anomalous neural circuit function in schizophrenia during a virtual Morris water task. Neuroimage 49, 3373–3384. 10.1016/j.neuroimage.2009.11.034 PubMed DOI PMC

Gaite L., Vázquez-Barquero J. L., Herrán A., Thornicroft G., Becker T., Sierra-Biddle D., et al. . (2005). Main determinants of global assessment of functioning score in schizophrenia: a European multicenter study. Compr. Psychiatry 46, 440–446. 10.1016/j.comppsych.2005.03.006 PubMed DOI

Golden C. J., Espe-Pfeifer P., Wachsler-Felder J. (2002). Neuropsychological Interpretation of Objective Psychological Tests. Fort Lauderdale, FL: Kluwer Academic Publishers; Nova Southeastern University.

Green M. F., Nuechterlein K. H., Gold J. M., Barch D. M., Cohen J., Essock S., et al. . (2004). Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry 56, 301–307. 10.1016/j.biopsych.2004.06.023 PubMed DOI

Hanlon F. M., Weisend M. P., Hamilton D. A., Jones A. P., Thoma R. J., Huang M., et al. . (2006). Impairment on the hippocampal-dependent virtual Morris water task in schizophrenia. Schizophr. Res. 87, 67–80. 10.1016/j.schres.2006.05.021 PubMed DOI

Harvey P. D., Sabbag S., Prestia D., Durand D., Twamley E. W., Patterson T. L. (2012). Functional milestones and clinician ratings of everyday functioning in people with schizophrenia: overlap between milestones and specificity of ratings. J. Psychiat. Res. 46, 1546–1552. 10.1016/j.jpsychires.2012.08.018 PubMed DOI PMC

Heinrichs R. W., Zakzanis K. K. (1998). Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12, 426–445. 10.1037/0894-4105.12.3.426 PubMed DOI

Heslegrave R. J., Awad A. G., Voruganti L. N. (1997). The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J. Psychiatry Neurosci. 22, 235–243. PubMed PMC

Houthoofd S. A., Morrens M., Sabbe B. G. (2008). Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clin. Ther. 30, 1565–1589. 10.1016/j.clinthera.2008.09.014 PubMed DOI

Ihara H., Berrios G. E., McKenna P. J. (2003). The association between negative and dysexecutive syndromes in schizophrenia: a cross-cultural study. Behav. Neurol. 14, 63–74. 10.1155/2003/304095 PubMed DOI PMC

Jones P. B., Barnes T. R., Davies L., Dunn G., Lloyd H., Hayhurst K. P., et al. . (2006). Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 63, 1079–1087. 10.1001/archpsyc.63.10.1079 PubMed DOI

Jones S. H., Thornicroft G., Coffey M., Dunn G. (1995). A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br. J. Psychiatry 166, 654–659. 10.1192/bjp.166.5.654 PubMed DOI

Kay S. R., Fiszbein A., Opler L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261–276. 10.1093/schbul/13.2.261 PubMed DOI

Keefe R. S., Bilder R. M., Davis S. M., Harvey P. D., Palmer B. W., Gold J. M., et al. . (2007). Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64, 633–647. 10.1001/archpsyc.64.6.633 PubMed DOI

Keefe R. S., Fenton W. S. (2007). How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr. Bull. 33, 912–920. 10.1093/schbul/sbm046 PubMed DOI PMC

Kessels R. P., van Zandvoort M. J., Postma A., Kappelle L. J., de Haan E. H. (2000). The corsi block-tapping task: standardization and normative data. Appl. Neuropsychol. 7, 252–258. 10.1207/S15324826AN0704_8 PubMed DOI

Khan A., Yavorsky W. C., Liechti S., DiClemente G., Rothman B., Opler M., et al. . (2013). Assessing the sources of unreliability (rater, subject, time-point) in a failed clinical trial using items of the positive and negative syndrome scale (PANSS). J. Clin. Psychopharmacol. 33, 109–117. 10.1097/JCP.0b013e3182776ebe PubMed DOI

Landgraf S., Krebs M. O., Olié J. P., Committeri G., van der Meer E., Berthoz A., et al. . (2010). Real world referencing and schizophrenia: are we experiencing the same reality? Neuropsychologia 48, 2922–2930. 10.1016/j.neuropsychologia.2010.05.034 PubMed DOI

Leeson V. C., Barnes T. R., Hutton S. B., Ron M. A., Joyce E. M. (2009). IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis. Schizophr. Res. 107, 55–60. 10.1016/j.schres.2008.08.014 PubMed DOI PMC

Lewis S., Lieberman J. (2008). CATIE and CUtLASS: can we handle the truth? Br. J. Psychiatry 192, 161–163. 10.1192/bjp.bp.107.037218 PubMed DOI

Lezak M. D., Howieson D. B., Bigler E. D., Tranel D. (2012). Neuropsychological Assessment. NewYork, NY: Oxford University Press.

Loh S., Lamond N., Dorrian J., Roach G., Dawson D. (2004). The validity of psychomotor vigilance tasks of less than 10-minute duration. Behav. Res. Methods Instrum. Comput. 36, 339–346. 10.3758/BF03195580 PubMed DOI

Makara-Studziñska M., Wołyniak M., Partyka I. (2011). The quality of life in patients with schizophrenia in community mental health service-selected factors. J. Pre-Clin. Clin. Res. 5, 31–34. Available online at: http://jpccr.eu/fulltxt.php?ICID=978221

Malla A., Payne J. (2005). First-episode psychosis: psychopathology, quality of life, and functional outcome. Schizophr. Bull. 31, 650–671. 10.1093/schbul/sbi031 PubMed DOI

Marková H., Laczó J., Andel R., Hort J., Vlček K. (2015). Perspective taking abilities in amnestic mild cognitive impairment and Alzheimer's disease. Behav. Brain Res. 281, 229–238. 10.1016/j.bbr.2014.12.033 PubMed DOI

Mas-Expósito L., Amador-Campos J. A., Gómez-Benito J., Lalucat-Jo L. (2011). The World Health Organization quality of life scale brief version: a validation study in patients with schizophrenia. Qual. Life Res. 20, 1079–1089. 10.1007/s11136-011-9847-1 PubMed DOI

Matsui M., Sumiyoshi T., Arai H., Higuchi Y., Kurachi M. (2008). Cognitive functioning related to quality of life in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 280–287. 10.1016/j.pnpbp.2007.08.019 PubMed DOI

Meltzer H. Y., McGurk S. R. (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25, 233–255. 10.1093/oxfordjournals.schbul.a033376 PubMed DOI

Mesholam-Gately R. I., Giuliano A. J., Goff K. P., Faraone S. V., Seidman L. J. (2009). Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 23, 315–336. 10.1037/a0014708 PubMed DOI

Milev P., Ho B. C., Arndt S., Andreasen N. C. (2005). Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am. J. Psychiatry 162, 495–506. 10.1176/appi.ajp.162.3.495 PubMed DOI

Money J., Walker H. T., Alexander D. (1965). A Standardized Road-map Test of Direction Sense. Baltimore, MD: Johns Hopkins Press.

Narvaez J. M., Twamley E. W., McKibbin C. L., Heaton R. K., Patterson T. L. (2008). Subjective and objective quality of life in schizophrenia. Schizophr. Res. 98, 201–208. 10.1016/j.schres.2007.09.001 PubMed DOI PMC

Nuechterlein K. H., Green M. F., Kern R. S., Baade L. E., Barch D. M., Cohen J. D., et al. . (2008). The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 165, 203–213. 10.1176/appi.ajp.2007.07010042 PubMed DOI

O'Leary D. S., Flaum M., Kesler M. L., Flashman L. A., Arndt S., Andreasen N. C. (2000). Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. J. Neuropsychiatry Clin. Neurosci. 12, 4–15. 10.1176/jnp.12.1.4 PubMed DOI

Osterrieth P. A. (1944). Le test de copie d'une figure complex: contribution a l'étude de la perception et de la memoir. Arch. Psychol. 30, 286–356.

Paradis M. (2008). Bilingualism and neuropsychiatric disorders. J. Neurolinguistics 21, 199–230. 10.1016/j.jneuroling.2007.09.002 DOI

PEBL (2012). The Psychology Experiment Building Language. Version 0.12, Test Battery 0.7. Michigan Technological University.

Peuskens J., Demily C., Thibaut F. (2005). Treatment of cognitive dysfunction in schizophrenia. Clin. Ther. 27(Suppl. A), S25–S37. 10.1016/j.clinthera.2005.07.015 PubMed DOI

Peuskens J., Gorwood P. (2012). How are we assessing functioning in schizophrenia? A need for a consensus approach. Eur. Psychiatry 27, 391–395. 10.1016/j.eurpsy.2011.02.013 PubMed DOI

Piskulic D., Olver J. S., Norman T. R., Maruff P. (2007). Behavioural studies of spatial working memory dysfunction in schizophrenia: a quantitative literature review. Psychiatry Res. 150, 111–121. 10.1016/j.psychres.2006.03.018 PubMed DOI

Preiss M., Bartoš A., Čermáková R., Nondek M., Benešová M., Rodriguez M., et al. (2012). Neuropsychologická Baterie Psychiatrického Centra Praha. Praha: Psychiatrické centrum Praha.

Preiss M., Preiss J. (2006). Test Cesty. Bratislava, MD: Psychodiagnostika.

Prouteau A., Verdoux H., Briand C., Lesage A., Lalonde P., Nicole L., et al. . (2005). Cognitive predictors of psychosocial functioning outcome in schizophrenia: a follow-up study of subjects participating in a rehabilitation program. Schizophr. Res. 77, 343–353. 10.1016/j.schres.2005.03.001 PubMed DOI

Rajji T. K., Mulsant B. H. (2008). Nature and course of cognitive function in late-life schizophrenia: a systematic review. Schizophr. Res. 102, 122–140. 10.1016/j.schres.2008.03.015 PubMed DOI

Reed R. A., Harrow M., Herbener E. S., Martin E. M. (2002). Executive function in schizophrenia: is it linked to psychosis and poor life functioning? J. Nerv. Ment. Dis. 190, 725–732. 10.1097/00005053-200211000-00001 PubMed DOI

Reitan R. M., Wolfson D. (1985). The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tuscon, AZ: Neuropsychology Press.

Rey A. (1964). L'examen Clinique en Psychologie. Paris: Presses Universitaries de France.

Ritsner M. S. (2007). Predicting quality of life impairment in chronic schizophrenia from cognitive variables. Qual. Life Res. 16, 929–937. 10.1007/s11136-007-9195-3 PubMed DOI

Rocca P., Giugiario M., Montemagni C., Rigazzi C., Rocca G., Bogetto F. (2009). Quality of life and psychopathology during the course of schizophrenia. Compr. Psychiatry 50, 542–548. 10.1016/j.comppsych.2008.12.002 PubMed DOI

Rodriguez M. M. V. (2012). Feasibility of Non-Pharmacological Intervention in Therapy of Cognition Deficit in Czech Schizophrenia Patients - Computer-assisted Cognitive Remediation. Prague: Facutly of Arts Charles University.

Rossi A., Mancini F., Stratta P., Mattei P., Gismondi R., Pozzi F., et al. . (1997). Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr. Scand. 95, 40–43. 10.1111/j.1600-0447.1997.tb00371.x PubMed DOI

Roy-Byrne P., Dagadakis C., Unutzer J., Ries R. (1996). Evidence for limited validity of the revised global assessment of functioning scale. Psychiatr. Serv. 47, 864–866. 10.1176/ps.47.8.864 PubMed DOI

Schultz K. (1991). The Contribution of solution strategy to spatial performance. Can. J. Psychol. 45, 474–491. 10.1037/h0084301 DOI

Spohn H. E., Strauss M. E. (1989). Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J. Abnorm. Psychol. 98, 367–380. 10.1037/0021-843X.98.4.367 PubMed DOI

Stirling J., White C., Lewis S., Hopkins R., Tantam D., Huddy A., et al. . (2003). Neurocognitive function and outcome in first-episode schizophrenia: a 10-year follow-up of an epidemiological cohort. Schizophr. Res. 65, 75–86. 10.1016/S0920-9964(03)00014-8 PubMed DOI

Stuve T. A., Friedman L., Jesberger J. A., Gilmore G. C., Strauss M. E., Meltzer H. Y. (1997). The relationship between smooth pursuit performance, motion perception and sustained visual attention in patients with schizophrenia and normal controls. Psychol. Med. 27, 143–152. 10.1017/S0033291796004230 PubMed DOI

Tzeng D. S., Lung F. W., Chang Y. Y. (2004). Comparison of quality of life for people with schizophrenia and mental health of caregivers beteen commn-based and hospital-based services. Kaohsiung. J. Med. Sci. 20, 443–451. 10.1016/S1607-551X(09)70183-4 PubMed DOI

Vargas M. L., Sanz J. C., Marín J. J. (2009). Behavioral assessment of the dysexecutive syndrome battery (BADS) in schizophrenia: a pilot study in the Spanish population. Cogn. Behav. Neurol. 22, 95–100. 10.1097/WNN.0b013e318192cd08 PubMed DOI

Ventura J., Hellemann G. S., Thames A. D., Koellner V., Nuechterlein K. H. (2009). Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr. Res. 113, 189–199. 10.1016/j.schres.2009.03.035 PubMed DOI PMC

Wechsler D. (1997). Manual for the Wechsler Memory Scale-III. San Antonio, TX: Psychological Corporation.

Weniger G., Irle E. (2008). Allocentric memory impaired and egocentric memory intact as assessed by virtual reality in recent-onset schizophrenia. Schizophr. Res. 101, 201–209. 10.1016/j.schres.2008.01.011 PubMed DOI

WHO group (1998). Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol. Med. 28, 551–558. 10.1017/S0033291798006667 PubMed DOI

Wilson B. A., Alderman N., Burgess P. W., Emslie H., Evans J. J. (1996). Behavioural Assessment of the Dysexecutive Syndrome. London: Thames Valley Test Company.

Woods S. W. (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 64, 663–667. 10.4088/JCP.v64n0607 PubMed DOI

Theoretical Modeling of Cognitive Dysfunction in Schizophrenia by Means of Errors and Corresponding Brain Networks